Maria Grazia Calabrò

Maria Grazia Calabrò

Auto-generated profile, based on publicly available information

Maria Grazia Calabrò

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
GLGiovanni Landoni
Giovanni Landoni
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
AZAlberto Zangrillo
Alberto Zangrillo
EBElena Bignami
Elena Bignami
SDStefania D’aVolio
Stefania D’aVolio
GTGiorgio Torri
Giorgio Torri

25 May 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GLGiovanni Landoni
Giovanni Landoni
VLVladimir Lomivorotov
Vladimir Lomivorotov
GAGabriele Alvaro
Gabriele Alvaro
RLRosetta Lobreglio
Rosetta Lobreglio
APAntonio Pisano
Antonio Pisano
AZAlberto Zangrillo
Alberto Zangrillo
Acute left ventricular dysfunction is a major complication of cardiac surgery and is associated with increased mortality. Meta-analyses of small trials suggest that levosimendan may result in a higher rate of survival among patients undergoing cardiac surgery. We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving patients in whom perioperative hemodynamic support was indicated after cardiac surgery, according to prespecified criteria. Patients were randomly assigned to receive levosimendan (in a continuous infusion at a dose of 0.025 to 0.2 μg per kilogram of body weight per minute) or placebo, for up to 48 hours or until discharge from the intensive care unit (ICU), in addition to standard care. The primary outcome was 30-day mortality. The trial was stopped for futility after 506 patients were enrolled. A total of 248 patients were assigned to receive levosimendan and 258 to receive placebo. There was no significant difference in 30-day mortality between the levosimendan group and the placebo group (32 patients [12.9%] and 33 patients [12.8%], respectively; absolute risk difference, 0.1 percentage points; 95% confidence interval [CI], −5.7 to 5.9; P=0.97). There were no significant differences between the levosimendan group and the placebo group in the durations of mechanical ventilation (median, 19 hours and 21 hours, respectively; median difference, −2 hours; 95% CI, −5 to 1; P=0.48), ICU stay (median, 72 hours and 84 hours, respectively; median difference, −12 hours; 95% CI, −21 to 2; P=0.09), and hospital stay (median, 14 days and 14 days, respectively; median difference, 0 days; 95% CI, −1 to 2; P=0.39). There was no significant difference between the levosimendan group and the placebo group in rates of hypotension or cardiac arrhythmias. In patients who required perioperative hemodynamic support after cardiac surgery, low-dose levosimendan in addition to standard care did not result in lower 30-day mortality than placebo. (Funded by the Italian Ministry of Health; CHEETAH ClinicalTrials.gov number, NCT00994825.)

1 August 2004 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
TBTiziana Bove
Tiziana Bove
MCMaria Grazia Calabrò
Maria Grazia Calabrò
GLGiovanni Landoni
Giovanni Landoni
GAGiacomo Aletti
Giacomo Aletti
GMGiovanni Marino
Giovanni Marino
AZAlberto Zangrillo
Alberto Zangrillo

1 January 2007 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
GLGiovanni Landoni
Giovanni Landoni
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
JTJames A. Tumlin
James A. Tumlin
TBTiziana Bove
Tiziana Bove
MLMonica De Luca
Monica De Luca
AZAlberto Zangrillo
Alberto Zangrillo

3 December 2014 in JAMA
Verified
Journal Article
Open access
PDF file
TBTiziana Bove
Tiziana Bove
AZAlberto Zangrillo
Alberto Zangrillo
FGFabio Guarracino
Fabio Guarracino
GAGabriele Alvaro
Gabriele Alvaro
BPBruno Persi
Bruno Persi
GLGiovanni Landoni
Giovanni Landoni
More than 1 million patients undergo cardiac surgery every year in the United States and Europe alone.1 One of its most common complications is acute kidney injury (AKI), which is associated with morbidity and mortality.2 Moreover, AKI requiring renal replacement therapy (RRT) (dialysis) affects approximately 5% of patients admitted to the intensive care unit (ICU), is associated with a mortality rate of up to 60%,3 and markedly increases the cost of care.

21 June 2005 in Circulation
Verified
Journal Article
Closed access
TBTiziana Bove
Tiziana Bove
GLGiovanni Landoni
Giovanni Landoni
MCMaria Grazia Calabrò
Maria Grazia Calabrò
GAGiacomo Aletti
Giacomo Aletti
GMGiovanni Marino
Giovanni Marino
AZAlberto Zangrillo
Alberto Zangrillo
Background— Acute renal failure is a serious complication of cardiac surgery causing high morbidity and mortality. The aim of this study was to evaluate the usefulness of fenoldopam, a specific agonist of the dopamine-1 receptor, in patients at high risk of perioperative renal dysfunction. Methods and Results— A prospective single-center, randomized, double-blind trial was performed after local ethical committee approval and after written consent was obtained from 80 patients undergoing cardiac surgery. Patients received either fenoldopam at 0.05 μg/kg per minute or dopamine at 2.5 μg/kg per minute after the induction of anesthesia for a 24-hour period. All these patients were at high risk of perioperative renal dysfunction as indicated by Continuous Improvement in Cardiac Surgery Program score >10. Primary end point was defined as 25% creatinine increase from baseline levels after cardiac surgery. The 2 groups (fenoldopam versus dopamine) were homogeneous cohorts, and no difference in outcome was observed. Acute renal failure was similar: 17 of 40 (42.5%) in the fenoldopam group and 16 of 40 (40%) in the dopamine group ( P =0.9). Peak postoperative serum creatinine level, intensive care unit and hospital stay, and mortality were also similar in the 2 groups. Conclusions— Despite an increasing number of reports of renal protective properties from fenoldopam, we observed no difference in the clinical outcome compared with dopamine in a high-risk population undergoing cardiac surgery.